News
FDA Grants Breakthrough Designation to AlphaMedix for Advanced Neuroendocrine Tumor Treatment
The FDA has granted breakthrough therapy designation to AlphaMedixTM (212Pb-DOTAMTATE) for treating adults with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), marking it as the first targeted
“Kath Bowl 2024” Raises Awareness, Funds for the Katherine Mueller NET Research Fund
“Kath Bowl” is an annual event organized by Katherine Mueller’s husband, Matt. “We hold this event every year to celebrate Katherine’s heavenly birthday,” said Matt.
FDA Paves Way for New Liver Tumor Treatment with Histotripsy
The U.S. Food and Drug Administration recently authorized a new technology called histotripsy to treat tumors in the liver, including neuroendocrine tumors. The noninvasive Edison®
Understanding Survival Factors in Lung Neuroendocrine Tumors: Insights from the California Cancer Registry
In 2019, Claire Mulvey, MD, received a NETRF Mentored Research Award to study the trends in incidence and survival outcomes for lung NETs. The goal
2024 NETRF Research Grant Opportunities – Letters of Intent Due by March 18, 2024
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to announce its 2024 Request for Applications. We’re seeking transformative research proposals in basic, translational, and clinical
NETTER-2 Trial Shows Lutathera® as First-Line Treatment Significantly Reduces Disease Progression or Death
Lutathera®, when given with long-acting release octreotide, reduces the risk of disease progression or death in those with newly diagnosed Grade 2 and 3 advanced
NETRF Awards Eleven Research Grants to Study Neuroendocrine Cancer
U.S. & International Scientists to focus on drug therapies, radiopharmaceuticals, and progression of NETs [BOSTON, MA, January 17, 2024–] The Neuroendocrine Tumor Research Foundation (NETRF)
Growth-factor Dependence in Lung Neuroendocrine Tumors
Lung neuroendocrine tumors (NETs) are graded as typical or atypical carcinoids based on how quickly the tumor cells divide. They exhibit diverse clinical behaviors and
Exploring Midgut NETs Through the Lens of the Microbiome
Midgut neuroendocrine tumors (NETs), such as small intestinal NETs, originate in the neuroendocrine cells of the midgut, a part of the digestive system, and have
Crinetics Announces Positive Results From Phase II Study of Paltusotine
The initial findings of a Phase 2 study have shown that the investigational drug paltusotine may significantly reduce both the frequency and intensity of bowel